(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
21 July 2011 (21.07.2011)

PCT

(10) International Publication Number
WO 2011/086099 A1

(51) International Patent Classification:
C07D 401/12 (2006.01) *C07D 413/04* (2006.01)
C07D 401/14 (2006.01) *C07D 471/04* (2006.01)
C07D 403/10 (2006.01) *C07D 487/04* (2006.01)
C07D 403/12 (2006.01) *A61K 31/4196* (2006.01)
C07D 403/14 (2006.01) *A61P 25/28* (2006.01)

(21) International Application Number:
PCT/EP2011/050350

(22) International Filing Date:
12 January 2011 (12.01.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10150892.7 15 January 2010 (15.01.2010) EP
10171292.5 29 July 2010 (29.07.2010) EP

(71) Applicant *(for all designated States except US)*: **ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC** [US/US]; 1125 Trenton-Harbourton Road, Titusville, New Jersey 08560 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **VAN BRANDT, Sven, Franciscus, Anna** [BE/BE]; Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340 Beerse (BE). **DE CLEYN, Michel, Anna, Jozef** [BE/BE]; Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340 Beerse (BE). **GIJSEN, Henricus, Jacobus, Maria** [NL/NL]; Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340 Beerse (BE). **BERTHELOT, Didier, Jean-Claude** [FR/BE]; Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340 Beerse (BE). **SURKYN, Michel** [BE/BE]; Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340 Beerse (BE).

(74) Agent: **QUAGHEBEUR, Luc**; Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340 Beerse (BE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

(54) Title: NOVEL SUBSTITUTED TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS



(I)

(57) Abstract: The present invention is concerned with novel substituted triazole derivatives of Formula (I) wherein Het^1, R^1, R^2, A^1, A^2, A^3, A^4, L^1, and L^2 have the meaning defined in the claims. The compounds according to the present invention are useful as gamma secretase modulators. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

WO 2011/086099 A1